0001437749-26-016755
SEC filingGenprex reported a wider operating loss and net loss in Q1 FY2026 versus Q1 FY2025, reflecting intensified R&D investment; however, net cash used in operating activities improved year-over-year due to timing-related increases in accounts payable and R&D materials accruals.
Research and development expenses continue to represent the largest component of Genprex’s operating costs. As disclosed in Item 2 of the Management Discussion and Analysis, the decrease in operating income and net income reflects an increase in R&D materials and accounts payable associated with operating activities, as well as timing differences in the payment of certain operating activities between Q1 FY2026 and Q1 FY2025. These dynamics are consistent with the company’s ongoing advancement of its pipeline, including preclinical work supporting GPX-002 and clinical trial enrollment for Acclaim-1 and Acclaim-3. The accounting treatment for R&D costs — expensed as incurred, except for purchased materials held for future research, which are capitalized as R&D supplies — underscores the company’s focus on building infrastructure and inventory ahead of upcoming milestones.
Genprex intends to initiate clinical-scale production in a cGMP-compliant facility, a step critical to enabling IND-enabling toxicology studies and future clinical trials. This effort aligns with the FDA meeting follow-up plan, which includes continuing preclinical animal studies to finalize study design and advance toward regulatory submissions. All forward-looking statements remain subject to the customary cautionary language regarding uncertainty, risk, and the speculative nature of biopharmaceutical development timelines.